- Home
- IONS vs QFIN Comparison
IONS vs QFIN Comparison
Compare IONS & QFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- QFIN
- Stock Information
- Founded
- IONS 1989
- QFIN 2016
- Country
- IONS United States
- QFIN China
- Employees
- IONS N/A
- QFIN N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- QFIN Finance: Consumer Services
- Sector
- IONS Health Care
- QFIN Finance
- Exchange
- IONS Nasdaq
- QFIN Nasdaq
- Market Cap
- IONS 6.0B
- QFIN 7.0B
- IPO Year
- IONS 1991
- QFIN 2018
- Fundamental
- Price
- IONS $30.17
- QFIN $44.91
- Analyst Decision
- IONS Buy
- QFIN Strong Buy
- Analyst Count
- IONS 19
- QFIN 2
- Target Price
- IONS $59.24
- QFIN $45.10
- AVG Volume (30 Days)
- IONS 1.5M
- QFIN 2.3M
- Earning Date
- IONS 05-06-2025
- QFIN 03-16-2025
- Dividend Yield
- IONS N/A
- QFIN 2.85%
- EPS Growth
- IONS N/A
- QFIN 58.28
- EPS
- IONS N/A
- QFIN 5.66
- Revenue
- IONS $705,138,000.00
- QFIN $2,351,749,665.00
- Revenue This Year
- IONS N/A
- QFIN $4.84
- Revenue Next Year
- IONS $25.71
- QFIN $4.66
- P/E Ratio
- IONS N/A
- QFIN $8.03
- Revenue Growth
- IONS N/A
- QFIN 5.38
- 52 Week Low
- IONS $29.61
- QFIN $17.76
- 52 Week High
- IONS $52.34
- QFIN $48.94
- Technical
- Relative Strength Index (RSI)
- IONS 37.05
- QFIN 53.28
- Support Level
- IONS $31.04
- QFIN $43.30
- Resistance Level
- IONS $33.76
- QFIN $48.94
- Average True Range (ATR)
- IONS 1.16
- QFIN 2.44
- MACD
- IONS -0.30
- QFIN 0.10
- Stochastic Oscillator
- IONS 10.92
- QFIN 59.00
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About QFIN Qifu Technology Inc.
Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.